Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin® as a rescue therapy, in […]
Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation for the pivotal
Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin® efficacy in the ISO-CC-005 study
Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal investigator, and Dr. Alain Herrera,
Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be presented at ESMO 2017, taking
John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol
Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed in the ISO-FF-001 study. The
Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results last week at ESMO-GI which
Isofol Medical AB (publ) announced today that the last one of five additional study sites was initiated in Greece and
Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue after high-dose methotrexate in osteosarcoma
